Table 4.

Threshold effect analyses of the association of LHR, MHR, NHR, and PHR with MASLD and significant liver fibrosis

	OR (95% CI) P value
MASLD
Log LHR ≤ –0.337	0.527 (0.187–1.484) 0.2401
Log LHR > –0.337	2.091 (1.783–2.451) <0.0001
Log NHR ≤ 0.871	0.835 (0.502–1.391) 0.4973
Log NHR > 0.871	1.703 (1.409–2.059) <0.0001
Log PHR ≤ 6.75	0.243 (0.116–0.508) 0.0013
Log PHR > 6.75	2.042 (1.770–2.356) <0.0001
Significant liver fibrosis
Log LHR ≤ –0.086	1.171 (0.561–2.443) 0.6792
Log LHR > –0.086	1.785 (1.494–2.134) <0.0001
Log MHR ≤ –1.72	0.311 (0.164–0.590) 0.0019
Log MHR > –1.72	1.587 (1.236–2.038) 0.0017
Log NHR ≤ 1.139	0.417 (0.198–0.876) 0.0317
Log NHR > 1.139	1.979 (1.604–2.441) <0.0001
Log PHR ≤ 7.183	0.453 (0.232–0.884) 0.0308
Log PHR > 7.183	1.854 (1.367–2.514) 0.0008

Adjusted for age, sex, race/ethnicity, education level, poverty income ratio (PIR), marital status, smoking, physical activity, dietary energy intake, diabetes, hypertension, and BMI.

CI, confidence interval; LHR, lipoprotein-cholesterol ratio; MASLD, metabolic dysfunction-associated steatotic liver disease; MHR, monocyte-HDL-C ratio; NHR, neutrophil-HDL-C ratio; OR, odds ratio; PHR, platelet-HDL-C ratio.